Näytä suppeat kuvailutiedot

Intraoperative Flurbiprofen Treatment Alters Immune Checkpoint Expression in Patients Undergoing Elective Thoracoscopic Resection of Lung Cancer

Shu SH; Magnussen CG; Hu JC; Hu SS; Wang D; Xie LX; Chai XQ

dc.contributor.authorShu SH
dc.contributor.authorMagnussen CG
dc.contributor.authorHu JC
dc.contributor.authorHu SS
dc.contributor.authorWang D
dc.contributor.authorXie LX
dc.contributor.authorChai XQ
dc.date.accessioned2022-10-28T14:26:06Z
dc.date.available2022-10-28T14:26:06Z
dc.identifier.urihttps://www.utupub.fi/handle/10024/171342
dc.description.abstractObjectives: This study aimed to determine the effect of intraoperative administration of flurbiprofen on postoperative levels of programmed death 1 (PD-1) in patients undergoing thoracoscopic surgery. Materials and Methods: In this prospective double-blind trial, patients were randomized to receive intralipid (control group, n = 34, 0.1 mL/kg, i.v.) or flurbiprofen axetil (flurbiprofen group, n = 34, 50 mg, i.v.) before induction of anesthesia. PD-1 levels on T cell subsets, inflammation, and immune markers in peripheral blood were examined before the induction of anesthesia (T-0) and 24 h (T-1), 72 h (T-2), and 1 week (T-3) after surgery. A linear mixed model was used to determine whether the changes from baseline values (T-0) between groups were significantly different. Results: The increases in the percentage of PD-1((+))CD8((+)) T cells observed at T-1 and T-2 in the control group were higher than those in the flurbiprofen group (T-1: 12.91 +/- 1.65 vs. 7.86 +/- 5.71%, p = 0.031; T-2: 11.54 +/- 1.54 vs. 8.75 +/- 1.73%, p = 0.004), whereas no differences were observed in the changes in the percentage of PD-1((+))CD4((+)) T cells at T-1 and T-2 between the groups. Moreover, extensive changes in the percentage of lymphocyte subsets and inflammatory marker concentrations were observed at T-1 and T-2 after surgery and flurbiprofen attenuated most of these changes. Conclusions: Perioperative administration of flurbiprofen attenuated the postoperative increase in PD-1 levels on CD8((+)) T cells up to 72 h after surgery, but not after this duration. The clinical relevance of changes in PD-1 levels to long-term surgical outcome remains unknown.
dc.language.isoen
dc.publisherKARGER
dc.titleIntraoperative Flurbiprofen Treatment Alters Immune Checkpoint Expression in Patients Undergoing Elective Thoracoscopic Resection of Lung Cancer
dc.identifier.urlhttps://www.karger.com/Article/FullText/503166
dc.identifier.urnURN:NBN:fi-fe2021042826548
dc.relation.volume29
dc.contributor.organizationfi=sydäntutkimuskeskus|en=Research Centre of Applied and Preventive Cardiovascular Medicine (CAPC)|
dc.contributor.organization-code2607004
dc.converis.publication-id46658808
dc.converis.urlhttps://research.utu.fi/converis/portal/Publication/46658808
dc.format.pagerange159
dc.format.pagerange150
dc.identifier.jour-issn1011-7571
dc.okm.affiliatedauthorMagnussen, Costan
dc.okm.discipline3122 Syöpätauditfi_FI
dc.okm.discipline3122 Cancersen_GB
dc.okm.internationalcopublicationinternational co-publication
dc.okm.internationalityInternational publication
dc.okm.typeJournal article
dc.publisher.countrySveitsifi_FI
dc.publisher.countrySwitzerlanden_GB
dc.publisher.country-codeCH
dc.relation.doi10.1159/000503166
dc.relation.ispartofjournalMedical Principles and Practice
dc.relation.issue2
dc.year.issued2020


Aineistoon kuuluvat tiedostot

Thumbnail

Aineisto kuuluu seuraaviin kokoelmiin

Näytä suppeat kuvailutiedot